Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas
The patho-physiological role of somatostatin receptor subtypes (sst) in neuro endocrine diseases has gained enhanced scientific interest in the past few years. The development of novel somatotropin-release inhibiting factor analogs, both sst-specific and universal ligands, seem promising as a tool to further increase fundamental insights in sst function. Eventually, this research should result in novel medical therapeutic opportunities in patients suffering from neuro-endocrine diseases. In the present review, the functional role of sst in all types of pituitary adenomas, based on recent preclinical and clinical studies, is being discussed.
|Persistent URL||dx.doi.org/10.1530/eje.1.02350, hdl.handle.net/1765/36294|
van der Hoek, J., Lamberts, S.W.J., & Hofland, L.J.. (2007). Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. European Journal of Endocrinology. Supplement, 156(1). doi:10.1530/eje.1.02350